Thursday, August 25, 2011

Buy Ind-Swift - Fruits of R&D efforts around the corner

Accumulate now.  2011 is just the begining of ISLL R&D journey.. You look at their R&D pipeline and you would find that they have a stake in all major API's that are going off patent over the next five years. They have a DMF for atorvastatin, Quetiapine, pioglitazone, Letrozole, Imatinib, Duloxetine and what not.. You name a blockbuster product and they are into it.. I would recommend a strong buy.  Current sales of these potential opportunities  are
Lipitor - atorvastatin - $10b
Cymbalta - Duloxetine - $5b
Seroquel - Quetiapine - $5b
Actos - Pioglitazone - $4b
Femara - Letrozole - $1.5b
Post patent expiry the volume sales of these products tend to go up by as much as 100%. The cumulative sales from these API's that ISLL can generate is 300 crores.

No comments:

Post a Comment